DRG Epidemiology's coverage of small-cell lung cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of small-cell lung cancer for each country, as well as annualized case counts projected to the national population.

In addition to forecasting incident and prevalent patient populations, the number of drug-treatment opportunities at specific lines of therapy are also forecast across the world.

DRG Epidemiology's small cell lung cancer forecast will answer the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with small-cell lung cancer per year?
  • In developing countries, what impact will economic growth and development have on the number of people diagnosed with small-cell lung cancer per year?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of small-cell lung cancer over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graphical depiction of the patient flow between or within different disease states for the countries considered in this report. These patient flow diagrams are provided at the regional level, but may be requested for any specific country or forecast year.

In addition to the total number of cases for each forecast year, DRG Epidemiology also provides at least ten years of forecast data for the following small-cell lung cancer subpopulations:

  • Drug-treatable prevalent cases by metastatic status
  • Diagnosed extensive first-line drug-treatable population
  • Diagnosed incident cases by stage distribution status
  • Diagnosed limited drug-treatable population
  • Diagnosed prevalent cases by drug treatment potential status
  • Limited SCLC by resectability status

Note: coverage may vary by country.

Table of contents

  • Mature Markets
    • Introduction
      • Key Findings
    • Epidemiology Data
    • Methods
      • Newly Diagnosed Incidence
      • Stage Distribution
      • Diagnosed Prevalence
      • Recurrent Incidence
      • Drug-Treatable Population and Percentage Drug-Treated
    • Reference Materials
      • Literature Review
      • Risk/Protective Factors
      • Bibliography

Author(s): Nicole Zhang, MPH

Nicole Zhang is an Epidemiologist at Decision Resources Group. She focuses on the epidemiology of oncology and cardiovascular disorders. She holds an from Tufts Medical School where she specialized in epidemiology and biostatistics. She also holds a in Chemistry and Statistics from Mount Holyoke College. Prior to joining Decision Resources, she worked as a research analyst at Massachusetts General Hospital where she independently managed data from food information survey conducted in Chelsea, MA. She has also worked at Massachusetts Department of Public Health where she conducted secondary research in the fields of gestational diabetes.


Related Reports

Small Cell Lung Cancer | Landscape & Forecast | Disease Landscape & Forecast

For decades, the treatment landscape of small-cell lung cancer (SCLC) has been dominated by chemotherapy or chemoradiotherapy. In 2018, Bristol-Myers Squibb’s Opdivo became the first immune...

View Details

Small Cell Lung Cancer | Epidemiology | Extrapolated Worldwide Coverage

DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key renal cell carcinoma ...

View Details